QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
QQQ   298.44 (-1.16%)
AAPL   145.54 (-1.07%)
MSFT   261.50 (+0.15%)
FB   200.04 (+0.71%)
GOOGL   2,288.90 (-1.38%)
AMZN   2,216.21 (-1.99%)
TSLA   724.37 (-5.88%)
NVDA   172.64 (-2.50%)
BABA   86.48 (-1.72%)
NIO   14.55 (+1.68%)
AMD   94.24 (-0.93%)
CGC   5.73 (-3.21%)
MU   70.47 (-2.02%)
T   20.28 (+2.22%)
GE   74.63 (-0.56%)
F   13.05 (-3.33%)
DIS   105.18 (-2.00%)
AMC   11.71 (-0.85%)
PFE   50.67 (+1.50%)
PYPL   77.65 (-1.50%)
NFLX   186.51 (-0.60%)
NASDAQ:AVIR

Atea Pharmaceuticals (AVIR) Stock Forecast, Price & News

$7.51
+0.22 (+3.02%)
(As of 05/16/2022 12:00 AM ET)
Add
Compare
Today's Range
$7.05
$7.71
50-Day Range
$5.33
$7.51
52-Week Range
$5.31
$46.91
Volume
1.04 million shs
Average Volume
940,708 shs
Market Capitalization
$625.27 million
P/E Ratio
14.73
Dividend Yield
N/A
Beta
-0.58
30 days | 90 days | 365 days | Advanced Chart
Receive AVIR News and Ratings via Email

Sign-up to receive the latest news and ratings for Atea Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Atea Pharmaceuticals logo

About Atea Pharmaceuticals

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-777, an NS5A inhibitor; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 for the treatment of hepatitis C virous (HCV); and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, Zika virus, and coronaviridae viral infection, as well as Ruzasvir, an investigational oral, pan genotypic NS5A inhibitor for the treatment of chronic HCV infection. It has a license agreement with Merck & Co, Inc. for development and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Headlines

Atea Pharmaceuticals: Q1 Earnings Insights
Atea Pharmaceuticals (AVIR) to Release Earnings on Tuesday
See More Headlines

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:AVIR
Fax
N/A
Employees
59
Year Founded
N/A

Sales & Book Value

Annual Sales
$351.37 million
Cash Flow
$1.50 per share
Book Value
$8.17 per share

Profitability

Net Income
$121.19 million
Pretax Margin
23.06%

Debt

Price-To-Earnings

Miscellaneous

Free Float
67,939,000
Market Cap
$625.27 million
Optionable
Not Optionable

Company Calendar

Last Earnings
5/10/2022
Today
5/16/2022
Next Earnings (Estimated)
8/11/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

1.64 out of 5 stars

Medical Sector

953rd out of 1,423 stocks

Pharmaceutical Preparations Industry

473rd out of 678 stocks

Analyst Opinion: 0.8Community Rank: 3.6Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 1.3 5 -4 -3 -2 -1 -













Atea Pharmaceuticals (NASDAQ:AVIR) Frequently Asked Questions

Is Atea Pharmaceuticals a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Atea Pharmaceuticals in the last twelve months. There are currently 1 sell rating and 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Atea Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AVIR, but not buy additional shares or sell existing shares.
View analyst ratings for Atea Pharmaceuticals
or view top-rated stocks.

When is Atea Pharmaceuticals' next earnings date?

Atea Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Atea Pharmaceuticals
.

How were Atea Pharmaceuticals' earnings last quarter?

Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) issued its earnings results on Tuesday, May, 10th. The company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.58) by $0.07. Atea Pharmaceuticals had a net margin of 34.49% and a trailing twelve-month return on equity of 7.54%. During the same period last year, the business posted $0.34 earnings per share.
View Atea Pharmaceuticals' earnings history
.

What price target have analysts set for AVIR?

3 equities research analysts have issued twelve-month price targets for Atea Pharmaceuticals' stock. Their forecasts range from $7.00 to $9.00. On average, they anticipate Atea Pharmaceuticals' share price to reach $8.00 in the next twelve months. This suggests a possible upside of 6.5% from the stock's current price.
View analysts' price targets for Atea Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Atea Pharmaceuticals' key executives?
Atea Pharmaceuticals' management team includes the following people:
  • Dr. Jean-Pierre Sommadossi Ph.D., Founder, Chairman, CEO & Pres (Age 66, Pay $902.99k)
  • Dr. Janet M.J. Hammond M.D., Ph.D., Chief Devel. Officer (Age 61, Pay $728.32k)
  • Dr. Maria Arantxa Horga M.D., Chief Medical Officer (Age 53, Pay $367.56k)
  • Ms. Andrea J. Corcoran J.D., CFO, Exec. VP of Legal & Sec. (Age 60)
  • Mr. Wayne Foster CPA, CPA, Exec. VP & Chief Accounting Officer (Age 53)
  • Ms. Jonae R. Barnes, Sr. VP of Investor Relations & Corp. Communications
  • Mr. Ariyapadi N. Krishnaraj, VP of Marketing
  • Mr. Adel Moussa Ph.D., Exec. VP of Chemistry
  • Mr. Xiao-Jian Zhou Ph.D., Exec. VP of Early Stage Devel.
  • Mr. John F. Vavricka, Chief Commercial Officer (Age 58)
When did Atea Pharmaceuticals IPO?

(AVIR) raised $253 million in an initial public offering on Friday, October 30th 2020. The company issued 11,000,000 shares at a price of $22.00-$24.00 per share. J.P. Morgan, Morgan Stanley, Evercore ISI and William Blair acted as the underwriters for the IPO.

What is Atea Pharmaceuticals' stock symbol?

Atea Pharmaceuticals trades on the NASDAQ under the ticker symbol "AVIR."

Who are Atea Pharmaceuticals' major shareholders?

Atea Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (8.08%), BlackRock Inc. (7.96%), Federated Hermes Inc. (2.46%), State Street Corp (2.25%), Renaissance Technologies LLC (1.40%) and Acadian Asset Management LLC (1.02%).
View institutional ownership trends for Atea Pharmaceuticals
.

Which major investors are selling Atea Pharmaceuticals stock?

AVIR stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Russell Investments Group Ltd., PNC Financial Services Group Inc., Group One Trading L.P., UBS Group AG, Victory Capital Management Inc., American Century Companies Inc., and Citigroup Inc..
View insider buying and selling activity for Atea Pharmaceuticals
or view top insider-selling stocks.

Which major investors are buying Atea Pharmaceuticals stock?

AVIR stock was bought by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Vanguard Group Inc., BlackRock Inc., Acadian Asset Management LLC, Renaissance Technologies LLC, Los Angeles Capital Management LLC, JPMorgan Chase & Co., and Jupiter Asset Management Ltd..
View insider buying and selling activity for Atea Pharmaceuticals
or or view top insider-buying stocks.

How do I buy shares of Atea Pharmaceuticals?

Shares of AVIR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Atea Pharmaceuticals' stock price today?

One share of AVIR stock can currently be purchased for approximately $7.51.

How much money does Atea Pharmaceuticals make?

Atea Pharmaceuticals has a market capitalization of $625.27 million and generates $351.37 million in revenue each year. The company earns $121.19 million in net income (profit) each year or $0.51 on an earnings per share basis.

How many employees does Atea Pharmaceuticals have?

Atea Pharmaceuticals employs 59 workers across the globe.

What is Atea Pharmaceuticals' official website?

The official website for Atea Pharmaceuticals is www.ateapharma.com.

How can I contact Atea Pharmaceuticals?

The company can be reached via phone at 857-284-8891 or via email at [email protected].

This page was last updated on 5/16/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.